ACADIA Pharmaceuticals Inc.

Good day, ladies and gentlemen, and thank you for standing by. Welcome to Acadia Pharmaceuticals' third quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at Acadia. Please go ahead.

Good afternoon, and thank you for joining us on today's call to discuss Acadia's third quarter 2025 financial results. Joining me on the call today from Acadia are Catherine Owen-Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brand, Debut and New Plazit. Also joining us today is Elizabeth Thompson, Ph.D., Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark Schneier, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing thoughts before we open up the call to your questions. We are using supplemental slides which are available on our website's events and presentations section. Before proceeding, I would like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, future results, and financial guidance are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. Viewer cautions not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change, except as required by law. I'll now turn the call over to Catherine for opening remarks.

Thank you, Al. Good afternoon, everyone, and thank you for joining us today. I'm pleased to report another strong quarter for Acadia, with solid execution across our commercial portfolio and continued momentum, positions as well for a strong finish to 2025, as we lay the foundation for sustained growth into 2026 and beyond. We delivered total revenues of $278.6 million this quarter, up 11% from a year ago, reflecting the strength of our commercial portfolio. This performance underscores our ability to execute on multiple fronts while building for future growth. Starting with debut, we're very pleased with our progress. following the expansion of our field force earlier this year, the benefits of which are now starting to materialize. I'm excited to share that we achieved our largest sequential increase in referrals since launch. This meaningful sequential growth reflects the impact of our expanded team into the community setting, giving us confidence that we will continue to see benefits from our broadened physician reach. During the third quarter, they've generated 101.1 million in net sales, including contributions from both US sales and main patient supply programs outside the US. We ship the highest number of daily bottles ever in a single quarter. In total, we ship to over 1,000 unique patients globally, an exciting milestone for the company. Importantly, patient persistency remains stable. underscoring the sustained benefit they deliver to patients and their families. Moving to New Placid, we delivered an exceptional quarter with net sales of $177.5 million, marking our strongest sales quarter ever. The momentum we are now driving gives us tremendous confidence in New Placid's potential to unlock higher growth in the coming years. To ensure we capture this opportunity, we're making strategic investments in a meaningful field force expansion. The impact of this field team expansion, combined with our direct-to-consumer campaigns, creates a powerful combination that we believe will drive sustained growth and value maximization for Newcastle. We're looking to build on our commercial success by advancing our pipeline of novel product candidates, including the recent initiation of one phase two and one phase three trials. I'll now send the call over to Tom to cover our commercial performance.